NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl Maximilian Thielmann, Klaus Griewank, Julia Kretz et al.|European Journal of Cancer|2021Cited by 33
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl Maximilian Thielmann, Klaus Griewank, Johanna Matull et al.|European Journal of Cancer|2021Cited by 20
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Selma Ugurel, Andreas Stang et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 19
Correction: <i>Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination</i>Lucie Heinzerling, Michael Weichenthal, Elisabeth Livingstone et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 0